Robert W. McMahon
Known title: SVP & Chief Financial OfficerCIK: 0001608730
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Transaction History
| WST | ▼ Sell | Tax Withholding | 346 | $121K | 8/11/2026 | View on chart |
| WST | ▲ Buy | Option Exercise | 6,355 | — | 8/11/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 2,764 | $971K | 8/11/2026 | View on chart |
| WST | ▲ Buy | Option Exercise | 794 | — | 8/11/2026 | View on chart |
| OSUR | ▲ Buy | Grant | 46,106 | $0 | 6/3/2026 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 22,888 | $69K | 5/13/2026 | View on chart |
| WST | ▲ Buy | Option Exercise | 4,231 | — | 2/11/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 1,250 | $308K | 2/11/2026 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 7,317 | $23K | 7/31/2025 | View on chart |
| A | ▼ Sell | Tax Withholding | 3,499 | $384K | 5/22/2025 | View on chart |
| OSUR | ▲ Buy | Grant | 71,017 | $0 | 5/14/2025 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 6,427 | $17K | 5/13/2025 | View on chart |
| A | ▲ Buy | Grant | 5,385 | $681K | 3/5/2025 | View on chart |
| A | ▲ Buy | Grant | 6,423 | $887K | 11/27/2024 | View on chart |
| A | ▼ Sell | Tax Withholding | 5,775 | $773K | 11/22/2024 | View on chart |
| A | ▼ Sell | Tax Withholding | 2,196 | $276K | 11/19/2024 | View on chart |
| A | ▲ Buy | Grant | 7,835 | $985K | 11/19/2024 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,295 | $165K | 11/15/2024 | View on chart |
| OSUR | ▲ Buy | Grant | 19,943 | $0 | 5/14/2024 | View on chart |
| A | ▲ Buy | Grant | 29,641 | $3.7M | 11/22/2023 | View on chart |
| A | ▲ Buy | Grant | 7,312 | $907K | 11/22/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 2,429 | $275K | 11/17/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 504 | $58K | 11/16/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 664 | $75K | 11/15/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 4,248 | $474K | 11/14/2023 | View on chart |
| A | ▲ Buy | Grant | 16,687 | $1.9M | 11/14/2023 | View on chart |
| OSUR | ▲ Buy | Grant | 22,703 | $0 | 7/31/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,750 | $256K | 11/18/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 679 | $98K | 11/17/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 504 | $74K | 11/16/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 11,380 | $1.7M | 11/15/2022 | View on chart |
| A | ▲ Buy | Grant | 32,134 | $4.8M | 11/15/2022 | View on chart |
| A | ▲ Buy | Grant | 5,359 | $793K | 11/15/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,860 | $276K | 11/11/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 2,303 | $310K | 8/3/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,751 | $288K | 11/19/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 678 | $110K | 11/17/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 11,196 | $1.8M | 11/16/2021 | View on chart |
| A | ▲ Buy | Grant | 4,060 | $655K | 11/16/2021 | View on chart |
| A | ▲ Buy | Grant | 31,615 | $5.1M | 11/16/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,869 | $301K | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.